Recent studies have shown that particular IGF1R polymorphisms significantly increase the risk of early tumor progression in tamoxifen-treated ER+ breast cancer, and that inhibition of IGF1R activity enhances response to trastuzumab therapy [41, 42]. This evidence concerns the gene IGF1R and neoplasm.